Jane Street Group LLC grew its holdings in shares of Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) by 112.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 24,654 shares of the biotechnology company’s stock after buying an additional 13,054 shares during the quarter. Jane Street Group LLC’s holdings in Progenics Pharmaceuticals were worth $104,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also modified their holdings of the company. Advisor Group Inc. grew its holdings in shares of Progenics Pharmaceuticals by 2,466.1% during the fourth quarter. Advisor Group Inc. now owns 12,651 shares of the biotechnology company’s stock valued at $53,000 after buying an additional 12,158 shares during the last quarter. Pacer Advisors Inc. acquired a new position in shares of Progenics Pharmaceuticals during the third quarter valued at about $102,000. Fosun International Ltd grew its holdings in shares of Progenics Pharmaceuticals by 14.0% during the fourth quarter. Fosun International Ltd now owns 454,588 shares of the biotechnology company’s stock valued at $1,773,000 after buying an additional 56,000 shares during the last quarter. Teachers Advisors LLC grew its holdings in shares of Progenics Pharmaceuticals by 6.9% during the third quarter. Teachers Advisors LLC now owns 241,655 shares of the biotechnology company’s stock valued at $1,515,000 after buying an additional 15,696 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its holdings in Progenics Pharmaceuticals by 9.2% during the third quarter. Bank of New York Mellon Corp now owns 1,160,542 shares of the biotechnology company’s stock worth $7,277,000 after purchasing an additional 97,561 shares during the last quarter. Hedge funds and other institutional investors own 87.59% of the company’s stock.
Several research firms recently weighed in on PGNX. Zacks Investment Research upgraded shares of Progenics Pharmaceuticals from a “hold” rating to a “buy” rating and set a $5.25 price target on the stock in a report on Thursday, February 21st. BidaskClub upgraded shares of Progenics Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Monday, April 1st. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the stock. Progenics Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $10.35.
Progenics Pharmaceuticals stock opened at $4.85 on Friday. Progenics Pharmaceuticals, Inc. has a fifty-two week low of $3.62 and a fifty-two week high of $9.42. The stock has a market cap of $410.03 million, a P/E ratio of -7.70 and a beta of 2.45. The company has a debt-to-equity ratio of 0.39, a quick ratio of 6.15 and a current ratio of 6.15.
Progenics Pharmaceuticals (NASDAQ:PGNX) last released its quarterly earnings results on Thursday, March 14th. The biotechnology company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.03) by ($0.14). Progenics Pharmaceuticals had a negative return on equity of 59.85% and a negative net margin of 433.09%. The firm had revenue of $3.24 million for the quarter, compared to analysts’ expectations of $10.99 million. As a group, research analysts anticipate that Progenics Pharmaceuticals, Inc. will post -0.62 earnings per share for the current year.
WARNING: “Jane Street Group LLC Has $104,000 Stake in Progenics Pharmaceuticals, Inc. (PGNX)” was first posted by Zolmax and is owned by of Zolmax. If you are viewing this report on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this report can be read at https://zolmax.com/investing/jane-street-group-llc-has-104000-stake-in-progenics-pharmaceuticals-inc-pgnx/3051967.html.
About Progenics Pharmaceuticals
Progenics Pharmaceuticals, Inc, an oncology company, develops, manufactures, and commercializes pharmaceutical products and other technologies to target, diagnose, and treat cancer cancer in the United States and internationally. The company's product candidates include Azedra, a radiotherapeutic product candidate for the treatment of iobenguane scan positive, unresectable, and locally advanced or metastatic pheochromocytoma or paraganglioma for adult and pediatric patients; PyL, a clinical-stage fluorinated prostate specific membrane antigen (PSMA)-targeted PET/CT imaging agent for prostate cancer; and 1095, a PSMA-targeted Iodine-131 labeled small molecule, which is in Phase II clinical trial for the treatment of metastatic castration-resistant prostate cancer.
Recommended Story: What is a short straddle?
Want to see what other hedge funds are holding PGNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX).
Receive News & Ratings for Progenics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progenics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.